IM95 Xenograft Model Service for Gastric Cancer

The IM95 Xenograft Model Service for Gastric Cancer provides a robust, clinically relevant platform for evaluating therapeutic efficacy against moderately differentiated gastric adenocarcinoma. Alfa Cytology leverages validated IM95 cell lines and standardized protocols to deliver reproducible xenograft data, enabling precise preclinical assessment of novel anti-cancer agents in a physiologically relevant tumor microenvironment.

Overview of IM95 Xenograft Model for Gastric Cancer

The IM95 cell line was established from a moderately differentiated gastric adenocarcinoma resected from a 63-year-old Japanese male patient. It exhibits epithelial-like morphology, maintains hepatocyte growth factor (HGF) production, and demonstrates consistent tumorigenicity in vivo, making it a well-characterized tool for gastrointestinal oncology research. The modal chromosome number of 46 and a doubling time of approximately 25 hours further support its utility in preclinical modeling.

In xenograft applications, IM95 tumors recapitulate key histopathological features of human gastric adenocarcinoma and have been employed to evaluate oncogenic signaling---particularly PI3K/Akt pathway modulation---and drug sensitivity profiles. The model supports subcutaneous and orthotopic implantation strategies, with luciferase-engineered derivatives (IM95/CMV-Luc) available for longitudinal tumor monitoring via non-invasive bioluminescence imaging.

Figure 1. COX5A Expression in Gastric Cancer (GC) Tissues and Cell Lines. (Li, Dongyan, et al., 2025)

Cell Line Information: IM95

The IM95 cell line and its derivatives are deposited with the Japanese Collection of Research Bioresources (JCRB) and are widely utilized in gastric cancer mechanistic and translational studies. Key characteristics are summarized below.

Our Services

Alfa Cytology provides end-to-end IM95 Xenograft Model Services tailored to your preclinical research objectives. From cell line authentication and quality-controlled expansion to tumor implantation, in-life monitoring, and comprehensive endpoint analysis, our team ensures methodological rigor and data integrity at every stage. We support both standard subcutaneous and advanced orthotopic or luciferase-imaging protocols, enabling flexible study designs that align with your therapeutic development pipeline.

Workflow of IM95 Xenograft Model Construction

Alfa Cytology follows a standardized, quality-controlled workflow to construct IM95 xenograft models, ensuring reproducible tumor growth and reliable pharmacological readouts. Each stage is executed under strict biosafety and ethical guidelines.

1. Cell Line Authentication & Expansion: IM95 cells are retrieved from authenticated stocks, verified by STR profiling, and expanded under defined culture conditions (DMEM + 10% FBS + 10 mg/L insulin) to ensure genetic stability and viability prior to implantation.
2. Pre-Implantation Quality Control: Cells are harvested at optimal confluency, assessed for viability (>95%), mycoplasma negativity, and morphological integrity; only passage-matched, low-passage cells are qualified for inoculation.
3. Animal Preparation & Ethical Approval: Immunodeficient mice (e.g., NOD/SCID or nude) are acclimatized under pathogen-free conditions; all procedures are conducted under approved IACUC protocols with humane endpoints predefined.
4. Tumor Cell Inoculation: IM95 cells are resuspended in a 1:1 mixture of serum-free medium and Matrigel, then injected subcutaneously into the flank or orthotopically into the gastric wall, depending on study design.
5. In-Life Monitoring & Tumor Tracking: Tumor dimensions are measured by caliper twice weekly; for luciferase-expressing models (IM95/CMV-Luc), bioluminescence imaging is performed to monitor tumor burden and metastatic spread non-invasively.
6. Endpoint Analysis & Tissue Collection: Upon reaching predetermined tumor volume or study duration, animals are euthanized; tumors are excised, weighed, and processed for histopathology (H&E, IHC), biomarker analysis, and molecular profiling.

Figure 2: Schematic workflow illustrating the derivation and construction of the IM95 Xenograft Model at Alfa Cytology.

Case Study-IM95 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established subcutaneous IM95 xenografts in immunodeficient mice to evaluate a novel targeted therapeutic regimen. Tumors achieved measurable palpability within 10-14 days post-inoculation and exhibited consistent, dose-dependent growth kinetics suitable for pharmacological intervention. Endpoint analysis revealed significant modulation of tumor volume and biomarker expression in treated cohorts relative to vehicle controls, demonstrating the model's sensitivity to therapeutic efficacy. Full histopathological and molecular datasets are available upon request for client-specific benchmarking.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific expertise with operational excellence to deliver IM95 xenograft data that advances your preclinical decision-making. Our integrated service model minimizes variability and accelerates timeline execution.

• Authenticated, low-passage IM95 cell stocks with full STR documentation and mycoplasma certification.
• Flexible study designs encompassing subcutaneous, orthotopic, and bioluminescence imaging protocols.
• Standardized workflows compliant with IACUC and AAALAC guidelines, ensuring ethical and reproducible outcomes.
• Comprehensive endpoint capabilities including histopathology, immunohistochemistry, biomarker quantification, and molecular profiling.
• Dedicated project management with transparent reporting, real-time data access, and rapid turnaround timelines.

Contact Us

Ready to advance your gastric cancer therapeutic pipeline with a validated IM95 xenograft model? Please reach out to us today via our inquiry form or email to learn more about our IM95 Xenograft Model services.

For research use only. Not intended for any clinical use.